Showing results (391-400 of 554) with videos related to
Sort By:
Pageof 56
Internal Medicine Journal|December 9, 2014
Consensus guidelines for the use of empiric and diagnostic-driven antifungal treatment strategies in haematological malignancy, 2014C O Morrissey, N M Gilroy, N Macesic, et al.Plos One|May 12, 2011
Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expressionLiang Zhang, Manoj Bhasin, Rachel Schor-Bardach, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 21, 2020
Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell CarcinomaJean-François Martini, Elizabeth R Plimack, Toni K Choueiri, et al.European Urology|February 11, 2011
Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinomaKatherine M Krajewski, Mengye Guo, Annick D Van den Abbeele, et al.Frontiers in Oncology|December 6, 2024
Late radiation-related lymphopenia after prostate stereotactic body radiation therapy plus or minus supplemental pelvic irradiationKelly Gaudian, Min Jung Koh, Min Ji Koh, et al.Journal of Translational Medicine|April 8, 2021
The "Great Debate" at Melanoma Bridge 2020: December, 5th, 2020Paolo A Ascierto, Michael B Atkins, Alexander M Eggermont, et al.Melanoma Research|September 1, 2018
Clinicopathologic features correlated with paradoxical outcomes in stage IIC versus IIIA melanoma patientsSally Y Tan, Julie Najita, Xiaoxue Li, et al.European Journal of Cancer (Oxford, England : 1990)|January 7, 2021
Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trialMichael B Atkins, Elizabeth R Plimack, Igor Puzanov, et al.Cancer|March 1, 2014
Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitorsAllison Ackerman, Oliver Klein, David F McDermott, et al.Clinical Genitourinary Cancer|April 3, 2016
Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell CarcinomaKathleen M Mahoney, Susanna Jacobus, Rupal S Bhatt, et al.Pageof 56